Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Manage your formulary budget
|Title:||Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dih ydro-2H-indol-2-one-hydrochloride|
|Abstract:||The monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2H-indole-2-one hydrochloride has advantageous stability for formulation as a neuroleptic agent.|
|Inventor(s):||Allen; Douglas J. M. (New London, CT), Busch; Frank R. (Gales Ferry, CT), DiRoma; Sabeto A. (Uncasville, CT), Godek; Dennis M. (Glastonbury, CT)|
|Assignee:||Pfizer Inc. (New York, NY)|
1. 5-(2-( 4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-in dol-2-one hydrochloride monohydrate.
2. A pharmaceutical composition having neuroleptic activity comprising the compound according to claim 1 in an amount effective in the treatment of neuroleptic diseases, and a pharmaceutically acceptable carrier.
3. A method of treating neuroleptic diseases which comprises administering to a subject in need of treatment a neuroleptic amount of the compound according to claim 1.
4. A process for preparing the compound according to claim 1, which comprises reacting anhydrous 5-(2-(4-1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro -2-H-indol-2-one with aqueous hydrochloric acid, wherein the concentration of the hydrochloric acid in the reaction solution is about 0.7 M.